InterCure (IL:INCR)
TASE:INCR
Want to see IL:INCR full AI Analyst Report?
Top Page
Intercure
(TASE:INCR)
Select Model
Select Model
Rating:60Neutral
Price Target:
377.00
▼(-26.68% Downside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by mid-range financial performance (2025 cash flow and revenue improvement, but ongoing losses) and strong technical momentum. These positives are offset by weak valuation support due to negative earnings and the absence of dividend yield data.
Positive Factors
Improved cash generation
Material positive operating and free cash flow in 2025 strengthens liquidity and reduces near-term financing needs. Durable cash generation supports reinvestment in cultivation, retail and product development, enabling organic growth and operational resilience if management sustains discipline.
Negative Factors
Persistent net losses
Multi-year net losses and a negative net margin indicate the core business has not yet delivered sustainable profitability. Continued operating losses can erode equity, limit retained earnings for growth, and force reliance on external funding, raising execution and dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
Material positive operating and free cash flow in 2025 strengthens liquidity and reduces near-term financing needs. Durable cash generation supports reinvestment in cultivation, retail and product development, enabling organic growth and operational resilience if management sustains discipline.
Read all positive factors
Intercure (INCR) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪196.31M
Dividend YieldN/A
Average Volume (3M)91.19K
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue GrowthN/A
EPS GrowthN/A
CountryIL
Employees320
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.62
Shares Outstanding54,681,335
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Intercure Business Overview & Revenue Model
Company Description
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract ...
How the Company Makes Money
InterCure primarily makes money by selling medical cannabis products through two main channels: (1) wholesale/medical cannabis supply—selling cannabis flower and related products to third parties (such as pharmacies and other distributors) in Isra...
Intercure Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
58
Neutral
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 243.12M | 270.20M | 238.84M | 355.55M | 388.68M | 219.68M |
| Gross Profit | 40.61M | 33.18M | 30.23M | 105.09M | 155.08M | 91.13M |
| EBITDA | -79.49M | -7.29M | -51.31M | -23.90M | 70.23M | 31.17M |
| Net Income | -70.93M | -35.71M | -67.80M | -61.96M | 44.82M | 4.69M |
Balance Sheet | ||||||
| Total Assets | 751.76M | 690.55M | 762.57M | 786.61M | 958.01M | 686.32M |
| Cash, Cash Equivalents and Short-Term Investments | 51.58M | 46.67M | 78.65M | 101.33M | 232.79M | 196.55M |
| Total Debt | 179.34M | 183.01M | 211.40M | 195.68M | 255.16M | 108.91M |
| Total Liabilities | 319.52M | 294.19M | 364.90M | 329.55M | 436.53M | 227.13M |
| Stockholders Equity | 431.15M | 396.52M | 396.97M | 455.11M | 501.31M | 448.03M |
Cash Flow | ||||||
| Free Cash Flow | 8.95M | 13.29M | -71.30M | -56.25M | 31.52M | 10.99M |
| Operating Cash Flow | 12.20M | 16.84M | -66.93M | -53.63M | 51.27M | 25.02M |
| Investing Cash Flow | -4.33M | -1.99M | 17.69M | 4.77M | -142.50M | -65.21M |
| Financing Cash Flow | -34.85M | -46.66M | 26.45M | -82.89M | 120.45M | 197.94M |
Intercure Technical Analysis
Positive
514.20
Price Trends
250.56
Positive
271.45
Positive
379.84
Negative
Market Momentum
13.68
Negative
81.46
Negative
82.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Positive. The current price of 514.2 is above the 20-day moving average (MA) of 261.15, above the 50-day MA of 250.56, and above the 200-day MA of 379.84, indicating a neutral trend. The MACD of 13.68 indicates Negative momentum. The RSI at 81.46 is Negative, neither overbought nor oversold. The STOCH value of 82.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:INCR.
Intercure Peers Comparison
UnderperformOutperform
Sector (51)
IL:INCR
Intercure
359.00
-197.80
-35.52%
IL:TGTR
Together
244.30
-164.90
-40.30%
IL:TKUN
Tikun Olam Canb
1,401.00
1,363.50
3636.00%
IL:CNZN.M
Canzon-M
155.20
46.70
43.04%
IL:SEMG
Seach Medical
256.00
-3.30
-1.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.